Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NEG0W5RHfW6ldHnvckBCe3OjeR?= NH7SeIQxNjgQvF2= MoW2NlRp MnTB[ZRp[W6xbB?= Ml\O[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? NV35[XBUOjV5OEewO|k>
TE13 MVrGeY5kfGmxbjDBd5NigQ>? Mnf3NE4{|ryP M4\YT|I1cA>? MXP1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NEK4PGIzPTV5OU[2OS=>
TE13 M4HxUWFxd3C2b4Ppd{BCe3OjeR?= NEKzdmsxNjQQvF2= NX3ycmFpOjSq MnzqbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MYOyOVU4QTZ4NR?=
MEFs MWHGeY5kfGmxbjDBd5NigQ>? NUfwTnFkPc7:TR?= MV6xOog> NEDxeY1qdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? NETJPFMzPTR6Mk[zOC=>
SW480  MnfHSpVv[3Srb36gRZN{[Xl? NGrOZmwxNjIQvF2= MVK0PIg> M3jvdWROW09? MVHy[ZZmenOnczDFUXQ> NG\xZYYzPTR|NEm5Oy=>
PC3  NV3pUJNCTnWwY4Tpc44hSXO|YYm= MmfVNE4y|ryP M3\qSFQ5cA>? MnjCSG1UVw>? MoS3doV3\XK|ZYOgSW1V M4X5WVI2PDN2OUm3
SW480  M1zRZ2Z2dmO2aX;uJGF{e2G7 M4KzVFAvOc7:TR?= Mn73OFhp M3PtOWROW09? M4Tpd4F1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= M4DuNVI2PDN2OUm3
PC3  M1u1fGZ2dmO2aX;uJGF{e2G7 M3K1bVAvOc7:TR?= NFLYVGI1QGh? NGDDfGhFVVOR NFixWmRifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MkH2NlU1OzR7OUe=
SW480  MlnQSpVv[3Srb36gRZN{[Xl? M{\EclAvOc7:TR?= MkDtOFhp NGTQWpFFVVOR MnvxbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NXvVbXlSOjV2M{S5PVc>
PC3  MlHnSpVv[3Srb36gRZN{[Xl? NF\wVGoxNjIQvF2= M3LI[FQ5cA>? Mkm1SG1UVw>? MmTHbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? MV[yOVQ{PDl7Nx?=
A431 M{nmc2Fxd3C2b4Ppd{BCe3OjeR?= MYOyM|ExNzVyL{GwNI5O NVfO[FFVPDiq NY[2bmkzTE2VTx?= NUnKcolEcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To M1PpW|I2OzdzME[5
A431 NH:wUlBHfW6ldHnvckBCe3OjeR?= Mmi1OVBvVQ>? NEjReXYzNzZxMUKvNlRp MnzFSG1UVw>? M1LvWoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= M1TtNlI2OzdzME[5
MDA-MB-231 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYewb5VmOC14MEDuUS=> MVeyOIg> NXv4d4JXTE2VTx?= MoDKTWM2OCCxZjCxNFBvVQ>? NVvJ[3N7OjVzOUK3NlE>
MCF7 NETxNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LuOlAuPjBybl2= NYL5SGtNOjSq M4rIbGROW09? NVnrNmJoUUN3MDDv[kA4PW6P M3m2O|I2OTl{N{Kx
SKOV-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rYdVEuOTEQvF2= MnjtNlRp NY[2SHR1TE2VTx?= NFPZUJNKSzVyIH;mJFUvPs7:TR?= MorTNlUyPjl2OUG=
A549 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIiwZ5UyNTFyzszN NEPGXFgzPGh? M2nDOGROW09? M1HLZWlEPTBib3[gN{4z|ryP NGHBXW8zPTF4OUS5NS=>
SKOV-3 M2TLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ntXFAvOS1zzszN M1ftb|Q5cA>? MXLEUXNQ NXPjZnV2UUN3MDDv[kAxNjgQvF2= MYCyOVE3QTR7MR?=
A549 M1jETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rXUVAvOS1zzszN MojOOFhp M4HlXGROW09? MYjJR|UxKG:oIECuNljPxE1? Mlv6NlUyPjl2OUG=
SKOV-3 NXLjWplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m4Z|AvODFvMD65{txO MV[3Nog> Mmq0SG1UVw>? MWPJR|UxKG:oIECuN|LPxE1? MXiyOVE3QTR7MR?=
A549 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMlAyNTBwOd88US=> NVKyVlBbPzKq NF;0fW1FVVOR M1K1NWlEPTBib3[gNE4xPs7:TR?= M2PtWFI2OTZ7NEmx
HeLa NHTVOmhHfW6ldHnvckBCe3OjeR?= NHnHb4MzPTCwTR?= MnLwNVZp MVjEUXNQ MV\pcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi NYfzPWE6OjVzMU[2PFg>
CNE2 M162Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknzNVAxNTZyMH7N M1ftcFI1NzR6L{eybC=> NI[1R2tqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHmy[JUzPDl4OUmwNS=>
PC3 M{PLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWixNFAuOTByMH7N NX25TnJwOjSq NGXadJRKSzVyIH;mJFMxOG6P MoH3NlQ5PTR4NUi=
LNCaP NX\N[5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLOeGcyODBvMUCwNI5O NEPmeHUzPGh? MUjJR|UxKG:oIEOwNI5O NFv0fVEzPDh3NE[1PC=>
HeLa  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL5O5Qz|ryP MoPjOFhp NHzicoVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl M3LXSFI1QDR4MUO1
HMEC-1  NU\IVYdsTnWwY4Tpc44hSXO|YYm= MonvN|Axdk1? NIrYe44zPGh? NGjmTHhqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C MlTDNlQ4OTB4M{G=
HeLa M1XWO2Z2dmO2aX;uJGF{e2G7 MnG4NY1O Ml7PNE42cA>? MWfhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MlPuNlQ4ODd2N{S=
ACP02 NEHJPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHLXHZxOjVyL{O1NE82ODCwTR?= NX3nNGxzOjSq M3qwWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NX;UUodPOjR4Nki1OFc>
ACP03 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCyOVAwOzVyL{WwNI5O M{P6eVI1cA>? NIfpcGJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P Ml;YNlQ3Pjh3NEe=
U87 GBM M1WwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fJfFExOC9|MECvOVAxKG6P M4\X[|czKGh? M{nwV|ExOCViZYToZY5wdA>? MXHy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= NY\oeWtKOjR2NkS4OFE>
U87 GBM Ml21SpVv[3Srb36gRZN{[Xl? MkOwNVAxNzVyMDDOcS=> NIq1R4Q1QCCq NY\iVZZ4OTByJTDleIhidm:u MYnJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> MXSyOFQ3PDh2MR?=
RPE MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrNE4zNzBwND:wMlgwOSEQvF2= M4TyTlI1NzR6L{eyJIg> NXvhfohtTE2VTx?= MU\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDifUBk\WyuIHP5Z4xmKGG{cnXzeC=> M{\XbVI1PDV4NkCy
HT29  M3y3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxPFAhdk1? NGfrWFU4OiCq NWnPcHZbUUN3MDDv[kAyQDBibl2= NF;vVIIzPDN4OEK2OS=>
hMSCs MoTMSpVv[3Srb36gRZN{[Xl? MUC2MlI2KG6P MWeyOEBp MYHEUXNQ MX7zeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| MoDHNlQ{OTJ|NU[=
Huh7  NETuVG1HfW6ldHnvckBCe3OjeR?= M3HUXVAvOS9yLkWvNU4xKM7:TR?= NXzaOJRrOjSq MnOzd5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w NEfsXVYzPDJ4OU[3Ni=>
SKOV3 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\zXlgyOC5yNT2yJO69VQ>? MnSzNVAwOjRxNEigbC=> MlzuSG1UVw>? NVr2Sm5pdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M{fVUlI1OjJ|OECx
A2780 NHPhbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrEc4I3OC5yNT2yJO69VQ>? MoS4NVAwOjRxNEigbC=> M4fFdWROW09? MUft[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUmyOFIzOzhyMR?=
SRA01/04  M{T5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\sNWNGOC5{IN88US=> MoC5OFghcA>? NEHGSJBFVVOR MVTzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> NUmwNnZ4OjRzNUe4O|g>
HLEB3 M{\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;SbXQxNjJizszN MlHLOFghcA>? M4fSZWROW09? MUHzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M2DrPVI1OTV5OEe4
SRA01/04  M3XUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vMV|AvPC9yLkig{txO M{TvV|Q5KGh? NVHDcYdiTE2VTx?= NVvLWm5ucW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUnmOodZOjRzNUe4O|g>
HLEB3 NHS3OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor6NE41NzBwODFOwG0> NVPIcYVWPDhiaB?= M4HOZmROW09? NGHrZlFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXeyOFE2Pzh5OB?=
HCT116 M4CxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXzcHVPOC5{IN88US=> MmHCNVIhcA>? MlG3[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= Mm\rNlQyOjJ{M{G=
CA46 M1H2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKzM|YwOTJxMkSvOFghdk1? MWO0PEBp M4ixPIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MkTaNlQxPjR7NUG=
PMNs M{\YXWZ2dmO2aX;uJGF{e2G7 MVizNEBvVQ>? NH;aU4U1QCCq NGX6T25qdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> MYOyN|k5QDZzNx?=
H1299 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxxsDPxE4EoB?= NELuS2IzPC92OD:3NkBp NHXIW3JmfGijbn;s NXLIXnRIcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq NXzwepI2OjN7MU[2NFk>
A549 NGntU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XJTVAvOjVxMD61M|Eh|ryP M3vGe|I1NzR6L{eyJIg> NVjqbnI3\XSqYX7vcC=> NVfST2Y4cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= Mmq0NlM5Pjd7OUG=
H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[wMlI2NzBwNT:xJO69VQ>? MkWyNlQwPDhxN{KgbC=> NGrBN2hmfGijbn;s NYr3b2IzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3;re|I{QDZ5OUmx
A549 NIP2R21CeG:ydH;zbZMhSXO|YYm= Mor1NE42NzFizszN NFuxWZg1QCCq MYnleIhidm:u M4f1W4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mlr4NlM5Pjd7OUG=
H1299 MX7BdI9xfG:|aYOgRZN{[Xl? M1LUc|AvPS9zIN88US=> NYDjfGV4PDhiaB?= NUfD[Y1b\XSqYX7vcC=> MoLEbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYrMV4Q6OjN6Nke5PVE>
SUM149PT NUnSU5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXoXGdkOi95LkWvNVAh|ryP NGq3bGQ1QCCq MVHEUXNQ NVrLb3lvcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= NV;hcGUxOjN5OUK2N|g>
SUM190PT MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:1NE8yODBxMkWwJI5O MlWxOFghcA>? MkHGSG1UVw>? MWTpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> M2GxfFI{Pzl{NkO4
HCT1 NXjIUYl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlIwOS5yL{WuNEDPxE1? NYe0N3lyOTJxMkSvN|YwPDhiaB?= NI\2bJlqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MWWyN|c4ODByMB?=
Lovo NUmzR2l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILNUmYxNjJxMT6wM|UvOCEQvF2= MWixNk8zPC9|Nj:0PEBp MkXzbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnT1NlM4PzByMEC=
AGS NX\uU4lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HVSFAvODF3LUGg{txO NHzafFc4OiCq NWjFbZhQcW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NYq3U2NJOjN5NEWwNlQ>
Huh7 NFvpOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzPbWwyKM7:TR?= Ml\0NlQhcA>? MWPEUXNQ M4P1O5Jm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh NXrLVmFQOjN4NEO5N|M>
ECC1 M4jCV2Z2dmO2aX;uJGF{e2G7 NXTyfY4xPTByIH7N MoPhOUBl M1;qUGROW09? M1zB[Ylv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MnLpNlM2OzB5Nkm=
HEC1A MWHGeY5kfGmxbjDBd5NigQ>? MmDwOVAxKG6P MWi1JIQ> NV3SVGZjTE2VTx?= MnTVbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? Mn\ENlM2OzB5Nkm=
EN1 NGDqbHlHfW6ldHnvckBCe3OjeR?= NESxbII2ODBibl2= MUO1JIQ> M1L6VmROW09? MWrpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NHPkdZozOzV|MEe2PS=>
MFE296 MUfGeY5kfGmxbjDBd5NigQ>? MXq1NFAhdk1? M4DiZlUh\A>? NGPSPYRFVVOR NVnRPGtEcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MX2yN|U{ODd4OR?=
HASMCs M4[ySGZ2dmO2aX;uJGF{e2G7 MlPwNE02ODBibl2= MlLBOkBl NU\PW5Zw\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? MUeyN|UyQDR4Nx?=
U373 MknCSpVv[3Srb36gRZN{[Xl? Ml7xNE4zPS9yLkWvNUDPxE1? NHz2UHozPCCq NGTQSm5qdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= M3vFT|I{PDd2MUex
ARN8  MmTkSpVv[3Srb36gRZN{[Xl? MXiwMlA2NTJizszN M{HPdlI1KGh? NWTCSIx2emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? Ml;0NlM1PzB3NEC=
MCF7 MVvGeY5kfGmxbjDBd5NigQ>? NFTQcJkxNjB3LUKg{txO M1WxS|I1KGh? MoDWdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NX3V[YVyOjN2N{C1OFA>
H1299  MXrGeY5kfGmxbjDBd5NigQ>? NXXGdI9UOC5|M,MAl|HDqML3TR?= M1riSlI1NzR6IHi= Mn3aSG1UVw>? NFTlWnRqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 NInsRngzOzR4MUm3OS=>
H1299 M{LJVGZ2dmO2aX;uJGF{e2G7 M4ix[|AvPSEQvF2= M3f0NVQ5KGh? MV3EUXNQ MoCybY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NH\EOHEzOzR4MUm3OS=>
H1299 NUDnWJRzTnWwY4Tpc44hSXO|YYm= M1jSeVAvPSEQvF2= MWG0PEBp NXf6fWFYTE2VTx?= NFy2e5ZqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= MYmyN|Q3OTl5NR?=
MG-63  NXv0V255T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\aSYMxNjNizszN MorhNVIuQTZiaB?= MmrOSG1UVw>? MneybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MkfCNlM1PTF6MUe=
LM8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlMh|ryP MV[xNk06PiCq NIXrdmpFVVOR NUfVRopJcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NHr2cWgzOzR3MUixOy=>
K562 NUHtUHdLTnWwY4Tpc44hSXO|YYm= M3vRNFAvPSEQvF2= NFTSVWszPCCq MkTz[ZRp[W6xbB?= M4\vV4Rm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M2PQXlI{PDNyOUW3
HEL M{PnU2Z2dmO2aX;uJGF{e2G7 MnjMNE42KM7:TR?= M4H2XFI1KGh? M{jyRYV1cGGwb3y= M1\r[IRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NUTzeWFsOjN2M{C5OVc>
HL60 M{PBW2Fxd3C2b4Ppd{BCe3OjeR?= MnnHNUDPxE1? NFXDVXEzPCCq MXHpcoR2[2W|wrDj[YxtKGSnYYTo MmfjNlM1ODB3MUm=
KG1 MV3BdI9xfG:|aYOgRZN{[Xl? NUHJfIs{OSEQvF2= MnfXNlQhcA>? MlmwbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MmX0NlM1ODB3MUm=
Kazumi NYnVN5JPSXCxcITvd4l{KEG|c3H5 MVixJO69VQ>? M1TseFI1KGh? M3nW[4lv\HWlZYRCpINmdGxiZHXheIg> NV3Ie3J{OjN2MEC1NVk>
K562 MYnBdI9xfG:|aYOgRZN{[Xl? NHGwUGUyKM7:TR?= M3;ldVI1KGh? NYD0[XpGcW6mdXPld:Kh[2WubDDk[YF1cA>? NHTsRWczOzRyMEWxPS=>
THP1 NY[wXms6SXCxcITvd4l{KEG|c3H5 M3rTNVEh|ryP Mn7GNlQhcA>? MlHxbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NGO5NZAzOzRyMEWxPS=>
SH-SY5Y Mn7NSpVv[3Srb36gRZN{[Xl? MYSyOVAhdk1? M3nz[|E3KGh? M4\Ub4Np[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= MlHrNlM{OjZ2MkK=
HEK293 MVfGeY5kfGmxbjDBd5NigQ>? M{HkT|EhyrWPwrC= NW\0c2hUOThiaNMg MWDpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ MXmyN|I5PDh2OB?=
HTK MlvqSpVv[3Srb36gRZN{[Xl? NID3S4g1ODBibl2= NV75[Y9TPzJiaB?= M2fLcolvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> MX6yN|I5PDByMh?=
HTK NFLGO4RHfW6ldHnvckBCe3OjeR?= MYOxNFAuQDBybl2= NUDU[FB{PzJiaB?= MkK1Zoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? NVXsbVZKOjN{OESwNFI>
Caco-2  MWHGeY5kfGmxbjDBd5NigQ>? NWjPOW9HOSEEtV5CpC=> NHHMVHMzPCCq Mmrm[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w MW[yN|E6PTB5MB?=
HeLa MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvSFExOCCwTR?= MmjRNlQhcA>? MX7EUXNQ M1;2[2lEPTBib3[gNVAxdk1? NXLjeVF3OjNzNkW3OFg>
HeLa MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDSV2M1OCCwTR?= MnewOFghcA>? M{PP[GROW09? NXPsbIdtUUN3MDDv[kA1OG6P MWOyN|E3PTd2OB?=
HeLa M{W4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTDNlAhdk1? Mly2O|IhcA>? M{W2T2ROW09? NIDKfpFKSzVyIH;mJFIxdk1? NV6xZWpCOjNzNkW3OFg>
HeLa M4r2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxNE8{OC93MDDuUS=> NH[yOpo4OiCq MlfTSG1UVw>? NELjfmNqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> M1n4UVI{OTZ3N{S4
MDA-MB-231 NVrRWHcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoNlUuPDByIH7N MnnyOFghcA>? NV:xfGU5UUN3MDDv[kAzPjNwMn7NxsA> NXrieHN2OjNyNUWxPVg>
MCF-7  MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPmfIJXOjVvNECwJI5O NFriXVA1QCCq MlXtTWM2OCCxZjCyNlAvPG6P NVTF[GdTOjNyNUWxPVg>
ECC-1  NUfYbYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHZe4NPOTByIH7N M4rIbFI1KGh? MX3leIhidm:u M4rXXolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= M1O2TFI{ODJ6OECz
HEC-1A NUPWSFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rqWVExOCCwTR?= MnjHNlQhcA>? NYHoTHpn\XSqYX7vcC=> NEPkeZRqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= NUfTcJRiOjNyMki4NFM>
NHAC-kn Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDTZ4YyOC9zMECvOVAxKG6P M3ThVlEzKGh? MUnEUXNQ NIryRopKSzVyIH;mJFUxOG6P MVWyN|AyPzh5MR?=
A549 NH7OWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:yOVAhdk1? NInFUFE3NTd{IHi= NX7MVZZ2TE2VTx?= NUj6VndG[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? MmLBNlI6QTR5OEC=
MG-63 M1LyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyzNFAhdk1? M2HZSFEzKGh? MojYSG1UVw>? M4nzO4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? NYjKSHVDOjJ5OUmzN|g>
MG-63 NIHBVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33GeFMxOCCwTR?= MYCyOEBp NXezOXY5TE2VTx?= MnzobY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? MUGyNlc6QTN|OB?=
MG-63 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfrdIQ3OzByIH7N NXK0bZNXPDhiaB?= MWHEUXNQ MorZbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MViyNlc6QTN|OB?=
HL60  MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnEPWkyPTBvM{WwJI5O MUCyOEBp MnrmbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NELoVpIzOjd3M{ezPS=>
U937 NV7R[WhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfUSXAyPTBvM{WwJI5O NGTnTlIzPCCq MVfpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N M2iyWVIzPzV|N{O5
SCC-6 M1riXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBdo0zODBvM{KwNEBvVQ>? MoLvNVIwOjRxNEigbC=> Ml3pSG1UVw>? MVnpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M1XyclIzPTV{M{Kx
U87  MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml61NVAxNTNyMDDu[y=> M2ri[FI1KGh? MmHybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? MWGyNlI4ODh2OR?=
K562 M1LNS2Z2dmO2aX;uJGF{e2G7 NY\jOYlCOSEQvF2= Mlr6NVIhcA>? MYXEUXNQ MV;lcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MYmyNlE4QTF7OB?=
Reh NEL4NHpHfW6ldHnvckBCe3OjeR?= M{TH[FAvOy9zIN88US=> NH3jWI8yOiCq NEDZfVlFVVOR NW\mNXNT\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> M1e4e|IzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID